Infliximab

From WikiMD
Jump to navigation Jump to search

Infliximab, marketed as Remicade, is medication approved for treatment of autoimmune disorders such as Rheumatoid Arthritis.

Indications for Infliximab

  • adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy;
  • adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy;
  • patients with moderately to severely active rheumatoid arthritis in combination with methotrexate;
  • patients with active ankylosing spondylitis (arthritis of the spine);
  • patients with active psoriatic arthritis;
  • adult patients with chronic severe plaque psoriasis.

Information about Infliximab

Infliximab is a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe inflammatory bowel disease and rheumatoid arthritis.

Mechanism of action of Infliximab

Infliximab (in flix' i mab) is a mouse-human chimeric monoclonal antibody to TNFα which binds avidly to serum and tissue bound TNFα, causing its inactivation and degradation. Inhibition of TNFα activity leads to modulation of the inflammatory and pain pathways activated by this cytokine.

FDA approval information for Infliximab

Infliximab was approved for use in the United States in 1998 and current indications include rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and severe psoriasis, Crohn disease (adult and pediatric) and ulcerative colitis. Infliximab is considered a disease modifying antirheumatic drug (DMARD) and has been shown to improve symptoms as well as joint and cartilage damage in the inflammatory arthritides.

Dosage and administration for Infliximab

Infliximab is available in vials containing 100 mg under the brand name of Remicade. The dose of infliximab varies by indication (50 to 200 mg per intravenous infusion) and it is generally given at 1, 2 and 6 weeks, and then in a maintenance dose at 8 week intervals.

Side effects of Infliximab

Common side effects include rash and fever. Rare but potentially severe side effects include seizures, heart failure, renal failure, bone marrow suppression, hypersensitivity reactions and Stevens Johnson syndrome. TNFα antagonists are also capable of causing immune suppression, resulting in reactivation of microbial infections including tuberculosis and hepatitis B.

Liver safety of Infliximab

Infliximab has been linked to many instances of idiosyncratic acute liver injury and is a well known cause of reactivation of hepatitis B.

This article is a stub. YOU can help Wikimd by expanding it!

Articles on Infliximab

Wikipedia

Learn more about Infliximab

Help WikiMD

Find something you can improve? Join WikiMD as an an editor and help improve this page or others.

Apple bitten.svg

WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

W8MD logo

Ad. Tired of being overweight?. W8MD's insurance weight loss can HELP*

Lose weight King of Prussia, PA | Lose weight NYC | Lose weight NJ | Lose weight Philadelphia | Advertise

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Infliximab">Infliximab</a>

  • Individual results may vary for weight loss from our sponsors.

Our sponsors WikiMD is supported by W8MD weight loss, sleep and medical aesthetic centers.